Then, we further evaluated MAPK8IP2 expression in prostate cancer by analyzing TCGA (PRAD) and GEO (GSE70768) datasets, [the TCGA included unpaired samples (52 normal tissues vs. 499 tumor tissues) (Fig. 1B) and paired samples (52 pairs) (Fig. 1C); GSE70786 included unpaired samples (73 normal tissues vs. 125 tumor tissues) (Fig. 1D) and paired samples (73 pairs) (Fig. 1E)]. This evidence concerns the gene MAPK8IP2 and prostate cancer.